Perceptive Advisors’s Standard BioTools LAB Stock Holding History

Perceptive Advisors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-46,030	Closed	-$567K	–	115
2019 Q2	$567K	Hold	46,030	–	–	0.01%	94
2019 Q1	$612K	Buy	+46,030	New	+$485K	0.02%	91
2014 Q2	–	Sell	-3,070	Closed	-$135K	–	133
2014 Q1	$135K	Buy	3,070 +1,040	+51%	+$45.8K	0.01%	117
2013 Q4	$78K	Buy	+2,030	New	+$59.8K	0.01%	100

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors's LAB Position: Q3 2019 in Review

Perceptive Advisors sold out of Standard BioTools (LAB) in Q3 2019, closing a stake of 46,030 shares — an estimated $567K sold.

Perceptive Advisors first reported a position in LAB in Q4 2013 and held it in 4 quarters. The position peaked at $612K in Q1 2019. 125 funds tracked by Wall St. Rank hold LAB as of Q3 2019.

Perceptive Advisors reported no remaining Standard BioTools position as of Q3 2019 after selling out during the quarter.
Perceptive Advisors sold 46,030 Standard BioTools shares in Q3 2019, an estimated $567K.
Perceptive Advisors first reported a position in Standard BioTools in Q4 2013 and held it in 4 quarters.
Perceptive Advisors's Standard BioTools position peaked at $612K in Q1 2019.
125 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2019.

Based on Perceptive Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.